BioCentury | Jul 4, 2011
Finance

Analyst tracks

...partner at Axon Healthcare Partners and Molloy was a managing director of equity research at Caris & Co. ...
BioCentury | Jan 3, 2011
Financial News

Oragenics withdraws follow-on

...Inc. (OTCBB:ORNI), Alachua, Fla. Business: Dental, Infectious, Diagnostic Date announced: 12/22/10 Type: Follow-on Underwriters: ThinkEquity; Caris & Co. WIR...
BioCentury | Aug 30, 2010
Financial News

Oragenics proposes follow-on

...Follow-on To be raised: Up to $23 million Price prior: $0.29 Shares: TBD Underwriters: ThinkEquity; Caris & Co....
BioCentury | May 31, 2010
Financial News

Salix completes private placement of senior convertible notes

...5/27/10 Type: Private placement of senior convertible notes Raised: $300 million Underwriters: Merrill Lynch; Jefferies; Caris & Co....
BioCentury | Jan 18, 2010
Finance

Banker tracks

...healthcare investment and corporate banking at BMO Capital Markets. Moskowitz was director of research at Caris & Co....
BioCentury | Sep 14, 2009
Company News

Biovail, Cary neurology news

Biovail filed a patent infringement suit against Cary in the U.S. District Court for the District of Delaware, alleging that Cary's CPI-300 infringes Biovail's U.S. Patent No. 6,096,341 covering antidepressant Wellbutrin XL bupropion extended-release. CPI-300,...
BioCentury | Jun 29, 2009
Clinical News

CPI-300 regulatory update

FDA accepted for review an NDA from Cary for CPI-300 to treat major depressive disorder (MDD). The PDUFA date is Feb. 6, 2010. IntelGenx and Cary co-developed CPI-300 using IntelGenx's controlled-release drug delivery technology. IntelGenx...
BioCentury | Jun 29, 2009
Finance

Ebb & Flow

Novo's crossover ambitions Novo A/S has tripled its commitment to life sciences venture investment from roughly $100 million to $300 million annually. Last week, Novo unveiled its evergreen Novo Growth Equity fund, which will invest...
BioCentury | Jun 24, 2009
Company News

FDA accepts CPI-300 NDA

IntelGenx Corp. (TSX-V:IGX; OTCBB:IGXT) said FDA accepted for review an NDA from partner Cary Pharmaceuticals Inc. (Great Falls, Va.) for CPI-300 to treat major depressive disorder. The PDUFA date is Feb. 6, 2010. IntelGenx and...
BioCentury | Sep 22, 2008
Finance

Shaking in their shorts

...Growth Fund and prior to that worked at Merlin Biosciences. Banker tracks Jeff Swarz joined Caris & Co....
Items per page:
1 - 10 of 15
BioCentury | Jul 4, 2011
Finance

Analyst tracks

...partner at Axon Healthcare Partners and Molloy was a managing director of equity research at Caris & Co. ...
BioCentury | Jan 3, 2011
Financial News

Oragenics withdraws follow-on

...Inc. (OTCBB:ORNI), Alachua, Fla. Business: Dental, Infectious, Diagnostic Date announced: 12/22/10 Type: Follow-on Underwriters: ThinkEquity; Caris & Co. WIR...
BioCentury | Aug 30, 2010
Financial News

Oragenics proposes follow-on

...Follow-on To be raised: Up to $23 million Price prior: $0.29 Shares: TBD Underwriters: ThinkEquity; Caris & Co....
BioCentury | May 31, 2010
Financial News

Salix completes private placement of senior convertible notes

...5/27/10 Type: Private placement of senior convertible notes Raised: $300 million Underwriters: Merrill Lynch; Jefferies; Caris & Co....
BioCentury | Jan 18, 2010
Finance

Banker tracks

...healthcare investment and corporate banking at BMO Capital Markets. Moskowitz was director of research at Caris & Co....
BioCentury | Sep 14, 2009
Company News

Biovail, Cary neurology news

Biovail filed a patent infringement suit against Cary in the U.S. District Court for the District of Delaware, alleging that Cary's CPI-300 infringes Biovail's U.S. Patent No. 6,096,341 covering antidepressant Wellbutrin XL bupropion extended-release. CPI-300,...
BioCentury | Jun 29, 2009
Clinical News

CPI-300 regulatory update

FDA accepted for review an NDA from Cary for CPI-300 to treat major depressive disorder (MDD). The PDUFA date is Feb. 6, 2010. IntelGenx and Cary co-developed CPI-300 using IntelGenx's controlled-release drug delivery technology. IntelGenx...
BioCentury | Jun 29, 2009
Finance

Ebb & Flow

Novo's crossover ambitions Novo A/S has tripled its commitment to life sciences venture investment from roughly $100 million to $300 million annually. Last week, Novo unveiled its evergreen Novo Growth Equity fund, which will invest...
BioCentury | Jun 24, 2009
Company News

FDA accepts CPI-300 NDA

IntelGenx Corp. (TSX-V:IGX; OTCBB:IGXT) said FDA accepted for review an NDA from partner Cary Pharmaceuticals Inc. (Great Falls, Va.) for CPI-300 to treat major depressive disorder. The PDUFA date is Feb. 6, 2010. IntelGenx and...
BioCentury | Sep 22, 2008
Finance

Shaking in their shorts

...Growth Fund and prior to that worked at Merlin Biosciences. Banker tracks Jeff Swarz joined Caris & Co....
Items per page:
1 - 10 of 15